Histologically confirmed metastatic colorectal cancer, not amenable to curative resection
Histologically or cytologically confirmed GI malignancy for which mFOLFOX6 is considered an appropriate treatment (e.g., gastric cancer [GC], colorectal carcinoma, pancreatic adenocarcinoma)
In dose expansion (part 2), patients must have histologically or cytologically confirmed unresectable or metastatic melanoma, renal cell carcinoma, ovarian cancer, or colorectal cancer
Measurable, histologically/cytologically confirmed metastatic colorectal cancer (mCRC).
Histologically confirmed unresectable metastatic colorectal adenocarcinoma
Have a pathologically confirmed diagnosis of colorectal cancer, which is metastatic or otherwise unresectable
Histologically confirmed colorectal adenocarcinoma
Patients must have histologically or cytologically confirmed metastatic colorectal cancer.
Histologically confirmed diagnosis of colorectal adenocarcinoma
Patients must have histologically and or cytologically confirmed metastatic colorectal cancer
Histologically or cytologically-confirmed diagnosis of metastatic KRAS wildtype colorectal cancer (CRC)
Participants must have histologically or cytologically confirmed adenocarcinoma of colorectal or pancreatic origin
Histologically confirmed colorectal cancer
Have a diagnosis of histologically confirmed metastatic colorectal cancer to the liver (no other sites of metastatic disease)\r\n* Histologic confirmation of a colorectal primary tumor is acceptable if accompanied by radiographic evidence of metastatic disease
Patients with histologically confirmed KRAS positive metastatic colorectal cancer
Histologically or cytologically confirmed metastatic colorectal adenocarcinoma (colon, rectal, colorectal, appendiceal cancer) or small bowel that is not resectable
Patients must have a histologically documented peritoneal carcinomatosis from either colorectal or appendiceal adenocarcinoma
Histologically or cytologically confirmed colorectal adenocarcinoma.
Histologically or cytologically confirmed colorectal adenocarcinoma
Histologically confirmed unresectable metastatic colorectal adenocarcinoma
Histologically or cytologically confirmed colorectal adenocarcinoma, with metastatic disease documented on diagnostic imaging studies
Histologically confirmed stage IV colorectal adenocarcinoma without any prior systemic treatment
In dose escalation, patients must have histologically or cytologically confirmed metastatic disease from any solid tumor; in dose expansion, patients must have histologically or cytologically confirmed metastatic melanoma, renal cell carcinoma, ovarian cancer, or colorectal cancer
Patients must have histologically or cytologically confirmed peritoneal surface malignancies from primary colorectal and appendiceal tumors
Histologically confirmed recurrent or metastatic colorectal cancer
Histologically proven colorectal adenocarcinoma
Patients with histologically confirmed metastatic colorectal cancer, who have received and/or progressed on a prior oxaliplatin-based chemotherapy regimen
Histologically and/or cytologically confirmed and radiographically evaluable refractory metastatic colorectal adenocarcinoma for which regorafenib would be considered a therapeutic option
A histologically or cytologically confirmed colorectal cancer that is metastatic, unresectable, or recurrent.
History of histologically confirmed colorectal adenocarcinoma metastatic to the liver with no clinical or radiographic evidence of extrahepatic disease; confirmation of diagnosis must be performed by the enrolling institution
Histologically or cytologically confirmed advanced metastatic or unresectable advanced colorectal cancer (CRC) or gastric cancer that is relapsed, refractory, or progressive after:
Histologically or cytologically confirmed diagnosis of metastatic colorectal cancer with a product related mutation in Ras (G12V, G12C, G12D, G12R, Q61L, Q61R, Q61H)
Patients with histologically proven, unresectable, evaluable metastatic colorectal cancer, by RECIST criteria
Histologically confirmed colorectal cancer with at least one measurable metastatic lesion by RECIST v 1.1, that is considered unresectable at baseline
Histologically confirmed colorectal cancer
Histologically or cytologically confirmed refractory colorectal cancer
Histologically or cytologically confirmed colorectal adenocarcinoma
Patient must have histologically or cytologically confirmed refractory colorectal cancer (CRC)
Histologically/cytologically proven colorectal carcinoma
Participants with histologically or cytologically confirmed advanced metastatic or unresectable colorectal cancer (CRC) that is relapsed, refractory, or progressive following at least 2 prior systemic regimens in the metastatic setting.
Patients must have histologically or cytologically confirmed colorectal or pancreatic carcinoma
Histologically confirmed diagnosis of colorectal adenocarcinoma
